Savara Inc.

Stocks

SVRA

US8051111016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:45:21 17/07/2026 BST			5-day change	1st Jan Change
5.585 ^USD	+1.18%		-7.13%	-7.13%

06-23	Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing	MT
06-08	Savara Inc. Announces CFO Changes	CI

Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026

Published on 05/12/2026 at 09:06 pm BST

S&P Capital IQ

Add MarketScreener to your sources

SAVARA INC.

+1.18%

Savara Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 37.28 million compared to USD 26.64 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.12 a year ago.

Add MarketScreener to your sources

Latest news about Savara Inc.

06-23	Savara Insider Sold Shares Worth $2,241,432, According to a Recent SEC Filing	MT
06-08	Savara Inc. Announces CFO Changes	CI
06-08	Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026	CI
05-18	Savara Inc Announces New Exercise Capacity Data From The IMPALA-2 Phase 3 Clinical Trial Of Molgramostim Inhalation Solution In Autoimmune Pulmonary Alveolar Proteinosis	CI
05-12	Savara Q1 Loss Widens	MT
05-12	Earnings Flash (SVRA) Savara Posts Q1 Per Share Loss $-0.15, vs. FactSet Est of $-0.13 Loss	MT
05-12	Savara Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Oppenheimer Adjusts Price Target on Savara to $11 From $9, Maintains Outperform Rating	MT
04-15	Savara announces the U.S. Food & Drug Administration (FDA) has extended the review period for the molgramostim inhalation solution (molgramostim) biologics license application (BLA) in autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	RE
04-15	Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application	MT
04-15	Savara Announces the U.S. Food & Drug Administration Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application in Autoimmune Pulmonary Alveolar Proteinosis	CI
04-07	Savara Inc. Announces MHRA Accepts Molbreevi Marketing Authorisation Application for Autoimmune PAP	CI
04-07	Savara Says UK Health Care Body Accepts Submission of Marketing Authorization Application for Molbreevi	MT
04-07	Savara announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted the Molbreevi* marketing authorisation application (MAA) for autoimmune pulmonary alveolar proteinosis (autoimmune PAP)	RE
03-30	Savara Says EMA Validates Marketing Authorization Application for Molbreevi to Treat Lung Disease	MT

Chart Savara Inc.

Duration

Period

SVRA: Dynamic Chart

Company Profile

Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Companyâ€™s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Employees

Sector

Biotechnology & Medical Research

More about the company